期刊
EXPERIMENTAL AND MOLECULAR MEDICINE
卷 51, 期 -, 页码 -出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/s12276-019-0250-2
关键词
-
资金
- Korea Health Industry Development Institute (KHIDI) [HI14C3319]
- National Research Foundation (Basic Science Research Program) [NRF-2018R1A6A1A03023718]
- National Research Foundation (Original Technology Research Program for Brain Science) [NRF-2018M3C7A1021858]
- Yonsei University [2018-22-0022]
- Yonsei University (Yonsei Frontier Lab)
- National Research Foundation of Korea [2018M3C7A1021858] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
Current technological advancements in clinical and research settings have permitted a more intensive and comprehensive understanding of Alzheimer's disease (AD). This development in knowledge regarding AD pathogenesis has been implemented to produce disease-modifying drugs. The potential for accessible and effective therapeutic methods has generated a need for detecting this neurodegenerative disorder during early stages of progression because such remedial effects are more profound when implemented during the initial, prolonged prodromal stages of pathogenesis. The aggregation of amyloid-beta (A beta) and tau isoforms are characteristic of AD; thus, they are considered core candidate biomarkers. However, research attempting to establish the reliability of A beta and tau as biomarkers has culminated in an amalgamation of contradictory results and theories regarding the biomarker concentrations necessary for an accurate diagnosis. In this review, we consider the capabilities and limitations of fluid biomarkers collected from cerebrospinal fluid, blood, and oral, ocular, and olfactory secretions as diagnostic tools for AD, along with the impact of the integration of these biomarkers in clinical settings. Furthermore, the evolution of diagnostic criteria and novel research findings are discussed. This review is a summary and reflection of the ongoing concerted efforts to establish fluid biomarkers as a diagnostic tool and implement them in diagnostic procedures.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据